Actively Recruiting

Phase Not Applicable
Age: 19Years - 90Years
All Genders
NCT07380854

Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism

Led by Seoul National University Bundang Hospital · Updated on 2026-02-02

338

Participants Needed

1

Research Sites

782 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG). The main questions this study aims to answer are: • Does levothyroxine reduce major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and new arrhythmias, in SCH patients undergoing CABG? Researchers will compare patients who take levothyroxine with those who do not. Participants will: * Be randomly assigned to either receive levothyroxine or not * Start the medication one day before surgery if assigned to the treatment group. * Have regular follow-up visits to check thyroid function and cardiovascular events for up to five years after surgery.

CONDITIONS

Official Title

Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism

Who Can Participate

Age: 19Years - 90Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 19 to 90 years
  • Patients scheduled to undergo coronary artery bypass graft (CABG) surgery
  • Subclinical hypothyroidism, defined as normal free thyroxine (free T4) level and thyroid-stimulating hormone (TSH) level greater than 4 micro IU/mL within 31 days before surgery
Not Eligible

You will not qualify if you...

  • Patients who underwent repeat or emergency CABG surgery
  • Use of levothyroxine within the previous 4 weeks
  • Use of antithyroid drugs (propylthiouracil, methimazole, or carbimazole) within the previous 3 months
  • Severe comorbid conditions with life expectancy less than 1 year, such as advanced malignancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Internal Medicine, Seoul National University Bundang Hospital

Seongnam-si, South Korea, 13620

Actively Recruiting

Loading map...

Research Team

M

Min Joo Kim, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here